Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response to COVID-19 Vaccine in MS Patients Treated With Ofatumumab
NCT04878211Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Jun 2021; status: terminated.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04878211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878211.